FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4318387346> ?p ?o ?g. }

• W4318387346 endingPage "205" @default.
• W4318387346 startingPage "195" @default.
• W4318387346 abstract "A rare yet severe neoplasia called malignant pleural mesothelioma (MPM) typically manifests itself in advanced stages. Despite some improvements in the treatment of patients with MPM, this malignancy continues to have a detrimental prognosis . The primary goal of the present study was to assess the associatin between ERCC1, RRM1, and thymidylate synthase (TS) expression and disease outcome in patients with malignant pleural mesothelioma (MPM) treated with either pemetrexed plus cisplatin or gemcitabine plus cisplatin.This prospective cohort study was done on ninety-one advanced MPM patients. The patients received either pemetrexed plus platinum (55 of 91) or gemcitabine plus platinum chemotherapy (36 of 91). Tissue biopsy was taken at time of diagnosis. Immunohistochemistry was used to assess the levels of ERCC1, RRM1, and TS transcription in tissue biopsies (paraffin embedded).Based on the findings, 70% of patients with low expression of TS had low expression of ERCC1, and 68% of patients with high expression of TS had high expression of ERCC1, suggesting a significat association between ERCC1 expression and TS expression (p=0.005). However, there was no relation between ERCC1 and RRM1 expression patterns (p= 0.296). In patients underwen platinum-based theraphy (n 91), a significant correlation was detected between low ERCC1 median High-scoring and longer progression time (TTP;9.6 v 5.3 months;P< .001) or overall survival (OS) (OS;18.1 v 9.1 months; P<0.001). A significant correlation was found between low TS protein expression and longer time progression (TTP; 11.8 v 5.4 months; P< .001) or OS (OS; 19.8 v 8.5 months; P <0.001) in patients undergoing pemetrexed plus platinum chemotherapy (n 55). Low RRM1 expression was accompanied by high progression free survival (TTP; 10.6 v 3.8 months) and OS (OS; 20.6 v 8.6 months) in patients receiving gemcitabine plus platinum chemotherapy. Based on the multivariate test results, the independent variables significantly affecting OS were tumor stage (HR: 2.3; 95% CI: 1.1-4.9; p= 0.021) and ERCC1 (HR: 2.7; 95% CI: 1.7-4.3; p < 0.001).Decreased TS protein expression can be indicative of greater responsivness to pemtrexed and of longer TTP and OS in individuals with advanced MPM (locally progressed or metastatic) who are receiving pemetrexed-based chemotheraphy. Low ERCC1 expressions in individuals with advanced MPM can predict increased PFS and OS, as well as a better responsivness to platinum-based chemotherapy. In patients with progressed MPM receiving gemcitabine plus cisplatin chemotherapy, lower RRM1 expression was associated with a better prognosis, longer PFS, and longer OS." @default.
• W4318387346 created "2023-01-29" @default.
• W4318387346 creator A5016320447 @default.
• W4318387346 creator A5043852977 @default.
• W4318387346 creator A5049368637 @default.
• W4318387346 creator A5053271744 @default.
• W4318387346 creator A5091477078 @default.
• W4318387346 date "2023-01-01" @default.
• W4318387346 modified "2023-10-14" @default.
• W4318387346 title "The Predictive Value of ERCC1, RRM1, and Thymidylate Synthase in Advanced Malignant Pleural Mesothelioma Patients Treated with Platinum-Based Chemotherapy" @default.
• W4318387346 cites W1573184761 @default.
• W4318387346 cites W1965595939 @default.
• W4318387346 cites W1971517620 @default.
• W4318387346 cites W2004718750 @default.
• W4318387346 cites W2024489444 @default.
• W4318387346 cites W2047348882 @default.
• W4318387346 cites W2054507362 @default.
• W4318387346 cites W2071842647 @default.
• W4318387346 cites W2079023451 @default.
• W4318387346 cites W2116751548 @default.
• W4318387346 cites W2118477571 @default.
• W4318387346 cites W2119116904 @default.
• W4318387346 cites W2142066824 @default.
• W4318387346 cites W2152005093 @default.
• W4318387346 cites W2162460126 @default.
• W4318387346 doi "https://doi.org/10.31557/apjcp.2023.24.1.195" @default.
• W4318387346 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36708568" @default.
• W4318387346 hasPublicationYear "2023" @default.
• W4318387346 type Work @default.
• W4318387346 citedByCount "0" @default.
• W4318387346 crossrefType "journal-article" @default.
• W4318387346 hasAuthorship W4318387346A5016320447 @default.
• W4318387346 hasAuthorship W4318387346A5043852977 @default.
• W4318387346 hasAuthorship W4318387346A5049368637 @default.
• W4318387346 hasAuthorship W4318387346A5053271744 @default.
• W4318387346 hasAuthorship W4318387346A5091477078 @default.
• W4318387346 hasBestOaLocation W43183873461 @default.
• W4318387346 hasConcept C104317684 @default.
• W4318387346 hasConcept C104451858 @default.
• W4318387346 hasConcept C123321153 @default.
• W4318387346 hasConcept C126322002 @default.
• W4318387346 hasConcept C134935766 @default.
• W4318387346 hasConcept C142724271 @default.
• W4318387346 hasConcept C143998085 @default.
• W4318387346 hasConcept C204232928 @default.
• W4318387346 hasConcept C2775934546 @default.
• W4318387346 hasConcept C2776694085 @default.
• W4318387346 hasConcept C2777240266 @default.
• W4318387346 hasConcept C2777407522 @default.
• W4318387346 hasConcept C2778239845 @default.
• W4318387346 hasConcept C2778397455 @default.
• W4318387346 hasConcept C2779309665 @default.
• W4318387346 hasConcept C2779399171 @default.
• W4318387346 hasConcept C2780258809 @default.
• W4318387346 hasConcept C2780456651 @default.
• W4318387346 hasConcept C55493867 @default.
• W4318387346 hasConcept C71924100 @default.
• W4318387346 hasConcept C86803240 @default.
• W4318387346 hasConceptScore W4318387346C104317684 @default.
• W4318387346 hasConceptScore W4318387346C104451858 @default.
• W4318387346 hasConceptScore W4318387346C123321153 @default.
• W4318387346 hasConceptScore W4318387346C126322002 @default.
• W4318387346 hasConceptScore W4318387346C134935766 @default.
• W4318387346 hasConceptScore W4318387346C142724271 @default.
• W4318387346 hasConceptScore W4318387346C143998085 @default.
• W4318387346 hasConceptScore W4318387346C204232928 @default.
• W4318387346 hasConceptScore W4318387346C2775934546 @default.
• W4318387346 hasConceptScore W4318387346C2776694085 @default.
• W4318387346 hasConceptScore W4318387346C2777240266 @default.
• W4318387346 hasConceptScore W4318387346C2777407522 @default.
• W4318387346 hasConceptScore W4318387346C2778239845 @default.
• W4318387346 hasConceptScore W4318387346C2778397455 @default.
• W4318387346 hasConceptScore W4318387346C2779309665 @default.
• W4318387346 hasConceptScore W4318387346C2779399171 @default.
• W4318387346 hasConceptScore W4318387346C2780258809 @default.
• W4318387346 hasConceptScore W4318387346C2780456651 @default.
• W4318387346 hasConceptScore W4318387346C55493867 @default.
• W4318387346 hasConceptScore W4318387346C71924100 @default.
• W4318387346 hasConceptScore W4318387346C86803240 @default.
• W4318387346 hasIssue "1" @default.
• W4318387346 hasLocation W43183873461 @default.
• W4318387346 hasLocation W43183873462 @default.
• W4318387346 hasLocation W43183873463 @default.
• W4318387346 hasOpenAccess W4318387346 @default.
• W4318387346 hasPrimaryLocation W43183873461 @default.
• W4318387346 hasRelatedWork W1967863863 @default.
• W4318387346 hasRelatedWork W1988428753 @default.
• W4318387346 hasRelatedWork W2136403887 @default.
• W4318387346 hasRelatedWork W2142448385 @default.
• W4318387346 hasRelatedWork W2162580433 @default.
• W4318387346 hasRelatedWork W2162653780 @default.
• W4318387346 hasRelatedWork W2381460883 @default.
• W4318387346 hasRelatedWork W2794807578 @default.
• W4318387346 hasRelatedWork W4231971187 @default.
• W4318387346 hasRelatedWork W4251539035 @default.
• W4318387346 hasVolume "24" @default.
• W4318387346 isParatext "false" @default.
• W4318387346 isRetracted "false" @default.

• next